DAY 1, 16th September 2020 (19:30 - 20:15) 

GC_Scientific-Leaders11.png
Prof. Hiddo L. Heerspink 

Professor,  Clinical Trials and Personalized Medicine

Clinical Pharmacologist, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Netherlands 

Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD trial)

Biography:

Prof. Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and subsequently received his PhD from the University Medical Center Groningen.

Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads and participates in clinical trials focused on renal and cardiovascular complications of type 2 diabetes. He is the co-PI of the DAPA-CKD trial. His main expertise includes clinical trial design and methodological aspects and statistical analyses of clinical trials.

Professor L. Heerspink is an editorial board member of the Clinical Journal of the American Society of Nephrology and served as guest editor for the scientific journals Diabetes Obesity & Metabolism and Nephrology Dialysis Transplantation. He has authored and co-authored over 300 peer-reviewed publications.

DAY 1, 16th September 2020 (20:15 – 21:00) 

2.jfif

The Changing Landscape for antiplatelet treatment after PCI

Biography:

Dr. Frankie Tam graduated from the University of Hong Kong in 2005. He received his training in Cardiology in Queen Mary Hospital Hong Kong and went to Harrington Heart and Vascular Institute, Cleveland, USA for overseas training in advanced interventional cardiology. He is currently the Associate Consultant in Queen Mary Hospital and Honorary Clinical Assistant Professor in the University of Hong Kong. His special interest is in the management of acute coronary syndrome, complex coronary intervention and structural heart disease intervention.

Dr. Frankie Tam Chor Cheung 

Honorary Clinical Assistant Professor, Cardiology Division,

Department of Medicine,  The University of Hong Kong